The coagulation panel is a group of blood tests used to assess how well your blood forms clots. The tests are critical for monitoring patients who are taking blood-thinning medications, evaluating unexplained bleeding or bruising, screening for inherited clotting disorders, and assessing patients before surgery or invasive procedures.
This article explains what each component of a coagulation panel measures, what abnormal results may mean, and how the tests are used in everyday medical care.
The reference range that applies to your result is the one printed on your laboratory report, not the typical ranges shown here. Reference ranges vary between laboratories based on the equipment used, the population tested, and individual factors such as age, sex, and pregnancy status. Always compare your result to the reference range printed on your own report, and discuss any abnormal result with your doctor.
How blood clotting works
When a blood vessel is injured, the body responds in two coordinated ways to stop the bleeding:
- Platelet plug formation. Tiny cell fragments called platelets rush to the site of injury and stick together to form an initial plug. This is the first line of defense against bleeding and is assessed primarily by the platelet count on the complete blood count (CBC).
- Coagulation cascade. A series of proteins called clotting factors (numbered I through XIII) are activated in a chain reaction that produces fibrin — a tough mesh of protein strands that strengthens the platelet plug into a stable clot. The coagulation panel assesses the function of this cascade.
Most clotting factors are made in the liver, which is why severe liver disease often leads to abnormal coagulation tests. Several clotting factors also depend on vitamin K, which is why vitamin K deficiency or vitamin K-blocking medications such as warfarin affect these tests.
Why is a coagulation panel done?
A coagulation panel is ordered for many reasons:
- To monitor anticoagulant medications. Patients taking warfarin (Coumadin) need regular INR testing to ensure the medication is in the therapeutic range — strong enough to prevent dangerous clots but not so strong that it causes bleeding. Patients on heparin may have PTT monitored.
- To investigate bleeding or bruising. Unexplained bruising, frequent nosebleeds, prolonged bleeding from minor cuts, heavy menstrual periods, or blood in the urine or stool may all prompt coagulation testing.
- To investigate unexplained clotting. Deep vein thrombosis, pulmonary embolism, or unusual clotting events may prompt testing for inherited clotting disorders.
- Before surgery or invasive procedures. A coagulation panel is sometimes performed before surgery, biopsies, or other procedures to ensure that bleeding can be controlled. It is particularly important before procedures with a high bleeding risk and in patients on blood-thinning medications.
- To assess liver function. Because most clotting factors are made in the liver, a prolonged PT can be a sign of significant liver disease. The PT/INR is one of the most important markers of severe liver dysfunction.
- In emergency settings. Coagulation tests are routinely performed in the emergency department and intensive care unit for patients with major bleeding, head injury, sepsis, or any condition that may affect clotting.
How is the test performed?
A coagulation panel is performed on a small sample of blood, usually drawn from a vein in the arm. The blood is collected into a tube containing a specific anticoagulant (sodium citrate) that prevents clotting in the tube. The laboratory then performs the tests by adding chemicals that activate clotting and timing how long it takes for a clot to form.
Coagulation samples need to be processed promptly, since the tests are time-sensitive. The blood draw must also fill the tube to the correct level — an underfilled tube can produce inaccurate results. The technologist drawing your blood will know to do this, but it is one reason coagulation tests sometimes need to be repeated. No fasting is required.
The main coagulation panel tests
Prothrombin time (PT)
Prothrombin time measures how long it takes for blood to form a clot when activated through what is called the extrinsic pathway of the coagulation cascade. Several clotting factors — particularly factors II (prothrombin), V, VII, and X — are involved. Most of these factors are made in the liver, and several depend on vitamin K.
A typical reference range for adults is approximately 11–13.5 seconds, though laboratories vary considerably and the test is more commonly reported alongside the INR.
Causes of a prolonged PT:
- Warfarin (Coumadin) and other vitamin K antagonist medications — by design
- Vitamin K deficiency, which can occur in malabsorption, prolonged antibiotic use, poor nutrition, or in newborns
- Severe liver disease — the liver loses its ability to make clotting factors
- Disseminated intravascular coagulation (DIC), a serious condition in which clotting factors are consumed faster than they can be replaced
- Inherited deficiencies of clotting factors II, V, VII, or X
- Some direct oral anticoagulants (DOACs) may slightly prolong PT, but PT is not the standard way to monitor these medications
Causes of a shortened PT are uncommon and usually not clinically significant.
International normalized ratio (INR)
The INR is a calculated number derived from the PT that adjusts for differences between laboratories and reagents. Without this adjustment, the same blood sample tested at different labs could produce different PT values, which would make it impossible to monitor warfarin therapy reliably across different settings.
For someone not taking anticoagulant medication, a typical INR is approximately 0.8–1.2.
For someone taking warfarin, the target INR depends on the reason warfarin was prescribed:
- INR 2.0–3.0 — the target for most indications, including atrial fibrillation, deep vein thrombosis, pulmonary embolism, and most mechanical heart valves
- INR 2.5–3.5 — the target for some higher-risk conditions, including certain mechanical heart valves and recurrent clotting on standard-intensity warfarin
An INR significantly above the target range increases bleeding risk; an INR below the target range increases the risk of clotting. INR is the basis for most warfarin dose decisions, and patients on warfarin typically have INR checked every few days when starting therapy and every two to four weeks once their dose is stable.
The INR is not useful for monitoring direct oral anticoagulants such as apixaban (Eliquis), rivaroxaban (Xarelto), edoxaban, or dabigatran (Pradaxa), which do not require routine monitoring through INR.
Partial thromboplastin time (PTT)
Partial thromboplastin time — also called activated partial thromboplastin time (aPTT) — measures how long it takes for blood to form a clot when activated through what is called the intrinsic pathway of the coagulation cascade. PTT involves clotting factors VIII, IX, XI, and XII, along with some of the same factors involved in the PT.
A typical reference range for adults is approximately 25–40 seconds.
Causes of a prolonged PTT:
- Heparin therapy — PTT is the standard test for monitoring intravenous heparin
- Hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency) — inherited disorders
- von Willebrand disease, the most common inherited bleeding disorder, sometimes prolongs PTT
- Severe liver disease
- Disseminated intravascular coagulation (DIC)
- Lupus anticoagulant — an autoantibody that paradoxically prolongs PTT in the laboratory but is associated with a higher risk of clotting in the body
- Inherited deficiencies of factors XI or XII (the latter does not usually cause clinical bleeding)
When PTT is prolonged for unclear reasons, additional testing — such as specific factor levels, mixing studies, and tests for the lupus anticoagulant — is often performed to identify the cause.
Other tests sometimes included in a coagulation panel
Depending on the clinical situation, other tests may be ordered alongside PT, INR, and PTT:
- Thrombin time (TT). Measures the final step of the coagulation cascade — the conversion of fibrinogen to fibrin. Used to detect heparin contamination, severe fibrinogen abnormalities, or interference from certain anticoagulant medications.
- Fibrinogen. Measures the level of fibrinogen, the protein converted to fibrin during clot formation. Low fibrinogen can be seen in DIC, severe liver disease, and inherited fibrinogen disorders. High fibrinogen is part of the inflammatory response and is not usually clinically actionable.
- D-dimer. A breakdown product of fibrin, raised when active clotting and clot breakdown are occurring. D-dimer is commonly used to help rule out deep vein thrombosis and pulmonary embolism in low-risk patients — a normal D-dimer makes these conditions unlikely. An elevated D-dimer is non-specific and can be raised by infection, surgery, pregnancy, cancer, and many other conditions.
- Specific clotting factor assays. Used to identify specific factor deficiencies such as hemophilia or factor VII deficiency.
- Mixing studies. Used to investigate prolonged PT or PTT and determine whether the prolongation is due to a factor deficiency (which can be corrected by mixing the patient’s blood with normal plasma) or to an inhibitor (which cannot be corrected).
- Anti-Xa level. A direct measurement of anticoagulant activity, used to monitor low-molecular-weight heparins (such as enoxaparin) and direct oral anticoagulants in specific situations such as kidney disease, extreme body weight, or pregnancy.
How the coagulation tests work together
The combination of PT and PTT results helps narrow down the source of a clotting problem:
- Prolonged PT, normal PTT: Suggests a problem with factor VII, vitamin K deficiency, early or mild liver disease, or warfarin therapy.
- Normal PT, prolonged PTT: Suggests a problem with factors VIII, IX, XI, or XII (including hemophilia), heparin therapy, von Willebrand disease, or a lupus anticoagulant.
- Both PT and PTT prolonged: Suggests a problem with a shared factor (II, V, X, or fibrinogen), severe liver disease, vitamin K deficiency that has progressed, DIC, or anticoagulant overdose.
- Both PT and PTT normal in a patient with bleeding: Suggests a problem with platelets, von Willebrand disease (which often does not significantly prolong PTT), factor XIII deficiency, or a blood vessel problem.
What happens after the coagulation panel?
If your results are within reference ranges and you are not taking anticoagulant medication, no further investigation is usually needed. If results are abnormal, the next steps depend on which test is abnormal and the clinical situation:
- Repeat the test. Inadequate sample volume in the tube and other technical issues can produce inaccurate results, particularly for PTT. A repeat test is sometimes the first step.
- Adjust anticoagulant doses. If you are taking warfarin or heparin and the result is outside the target range, your doctor will adjust the dose. Significant abnormalities may require holding the medication, giving vitamin K, or in severe cases administering a reversal agent.
- Investigate liver function. Persistently prolonged PT without an obvious cause typically prompts a liver panel to look for liver disease.
- Test for inherited bleeding disorders. Patients with unexplained bleeding may have specific factor levels measured, von Willebrand factor testing, or platelet function testing.
- Test for inherited clotting disorders. Patients with unexplained clotting may have specialized testing for thrombophilia, including factor V Leiden, prothrombin gene mutation, protein C, protein S, antithrombin, and antiphospholipid antibody testing.
- Refer to a hematologist. Persistent or unexplained coagulation abnormalities, particularly when bleeding or clotting is occurring, may prompt referral to a hematologist (specialist in blood disorders).
- Treat acute bleeding or clotting. Major bleeding may require transfusion of fresh frozen plasma, platelets, or specific clotting factor products. Major clotting may require initiation or escalation of anticoagulant therapy.
Questions to ask your doctor
- Were any of my coagulation tests outside the reference range?
- If I am on warfarin, is my INR in the target range for my condition?
- Could any of my medications, supplements, or recent illnesses be affecting my results?
- If my PT or PTT is prolonged, what additional testing do I need?
- Am I at risk for bleeding or clotting based on my results?
- Should I avoid any specific activities, medications, or procedures because of my results?
- Should the test be repeated, and if so, when?
- Should I be referred to a hematologist?
Related articles on MyPathologyReport.com